FDA Approves Half-Dose MRI Contrast Agent for Infants and Newborns

PRINCETON, NJ – February 20, 2026 – The U.S. Food and Drug Administration (FDA) has approved a significant label expansion for Elucirem™ (gadopiclenol), a magnetic resonance imaging (MRI) contrast agent, extending its use to pediatric patients aged 0-2 years, including term neonates. The announcement from Guerbet, a global specialist in medical imaging, marks a pivotal moment in pediatric radiology, offering a powerful diagnostic tool that requires only half the standard dose of gadolinium compared to other widely used agents.

This approval directly addresses long-standing concerns among clinicians and parents about gadolinium exposure in the youngest and most vulnerable patients. Elucirem™, a macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity, was first approved for adults in the U.S. in September 2022. Its expansion into neonatal and infant care provides a new option designed to minimize chemical exposure while maintaining the high-quality images essential for diagnosing complex medical conditions.

Addressing a Long-Standing Concern: Gadolinium in Children

For decades, GBCAs have been indispensable for enhancing the visibility of organs, blood vessels, and tissues during MRI scans, enabling the detection of lesions and abnormalities that might otherwise go unseen. However, their use has been accompanied by a persistent concern: gadolinium retention. Studies have shown that small amounts of the heavy metal can remain in the body for months or years, accumulating in organs such as the brain, bones, and skin.

While the clinical consequences of this retention in patients with normal kidney function are not yet fully established, the medical community has adopted a cautious approach, particularly for pediatric patients. Children are considered a higher-risk population due to their developing organs and longer life expectancy, which increases the potential for cumulative effects from repeated exposure over a lifetime. This concern is especially acute for infants and neonates, whose renal systems are still maturing, potentially affecting their ability to clear the agent from their bodies.

In response, regulatory bodies like the FDA have issued safety communications, and professional organizations such as the Society for Pediatric Radiology have long advocated for the principle of "as low as reasonably achievable" (ALARA) when dosing contrast media. The market has steadily shifted toward macrocyclic GBCAs, like Elucirem™, which have a more stable molecular structure that is less likely to release free gadolinium into the body compared to older, linear agents.

A New Standard of Care with High Relaxivity

The key innovation behind Elucirem™ is its unique combination of a macrocyclic structure and exceptionally high relaxivity. In layman's terms, relaxivity is a measure of a contrast agent's efficiency in brightening the MRI signal. Elucirem's high relaxivity means it is twice as effective as many conventional agents, allowing it to produce sharp, clear, and diagnostically robust images with just half the dose of gadolinium (0.05 mmol/kg versus the standard 0.1 mmol/kg).

This half-dose advantage is not just a marginal improvement; it represents a fundamental step forward in patient safety. By significantly reducing the amount of gadolinium administered, Elucirem™ directly mitigates the risk of long-term retention without compromising diagnostic accuracy.

Dr. Azam Eghbal, Medical Director of Pediatric Radiology at Children's Hospital of Orange County, highlighted this benefit in the company's announcement. "Our pediatric patients are still developing and often vulnerable and we want to consider that with everything we do," she stated. "One key asset of Elucirem™ is that, thanks to its higher relaxivity, we can get good image quality using only half the conventional gadolinium dose. That makes a real difference in terms of amount of gadolinium injected, especially for these young patients, without losing diagnostic accuracy."

The Clinical and Regulatory Pathway to Pediatric Approval

The FDA's decision to approve Elucirem™ for term neonates and infants is based on a thorough review of clinical data demonstrating its safety and efficacy in this specific population—a group for which clinical trial data is often scarce. This approval follows its successful adoption in adult imaging and a similar pediatric approval by the European Medicines Agency (EMA) in December 2023, signaling a strong and consistent global regulatory consensus on its benefits.

For children with chronic conditions who may require numerous MRI scans throughout their lives, the ability to reduce their total gadolinium burden is critical. "The new indication of Elucirem™ for pediatric patients, including term neonates, reflects our commitment to combining medical innovation and patient experience," said Jim Patterson, General Manager for Guerbet North America. He noted that the half-dose capability is "critical for patients, especially those requiring serial MRI examinations during their lifetime, as it reduces cumulative gadolinium exposure."

Like all GBCAs, Elucirem™ carries important safety warnings, including a boxed warning for Nephrogenic Systemic Fibrosis (NSF), a rare but serious condition linked to GBCAs in patients with impaired kidney function, and a warning against intrathecal (spinal) use. The most common adverse reactions reported in clinical trials were mild, including injection site pain, headache, and nausea.

Market Implications and the Road to Adoption

With this pediatric approval, Guerbet has strategically positioned Elucirem™ as a premium, safety-focused agent in the competitive contrast media market, which is dominated by major players like Bayer and Bracco Imaging. Interestingly, Guerbet and Bracco Imaging entered a worldwide collaboration in 2021 for the manufacturing and research of gadopiclenol, the active molecule in Elucirem™. This means the technology will be commercialized independently under separate brand names, potentially accelerating its availability and adoption.

The clinical value proposition—maintaining diagnostic quality while halving gadolinium exposure—provides a powerful incentive for hospitals and imaging centers to add Elucirem™ to their formularies. Its alignment with the ALARA principle makes it an attractive option for pediatric hospitals looking to establish the highest standards of patient safety. Widespread adoption will now depend on pricing, reimbursement negotiations with insurers, and the integration of the new agent into established pediatric imaging protocols. The compelling safety profile, however, is expected to be a significant driver in overcoming these hurdles, potentially reshaping the standard of care for contrast-enhanced MRI in the world's youngest patients.